Monday, January 31, 2011
So says Reuters:
U.S. biotech company Genzyme Corp and French drugmaker Sanofi-Aventis SA have reached an agreement in principle on the outlines of a merger deal, three sources familiar with the situation said on Monday.
The agreement in principle would include a so-called contingent value right (CVR), or a payout over time based on the performance of Genzyme's experimental multiple sclerosis drug, Lemtrada, the sources said.
Ugh, the earnout survived!